CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab
Status:
Not yet recruiting
Trial end date:
2025-09-01
Target enrollment:
Participant gender:
Summary
This is a phase IB/IIA trial to ensure the safety of CEND-1 in combination with with
Folfirinox with or without Panitumumab for treatment of pancreatic, colon and appendiceal
cancers